阿尼卡医疗 2026年季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April 21, 2026, there were 13,305,624outstanding shares of Common Stock, par value $0.01 per share. Part IFinancial Information Item 1.Condensed Consolidated Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025Condensed Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31,2026 and 2025Condensed Consolidated Statements of Stockholders’Equity for the three months ended March 31, 2026 and 2025Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025Notes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPart IIOther InformationItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures References in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” “our company,” and other similar references refer to AnikaTherapeutics, Inc. and its subsidiaries unless the context otherwise indicates. ANIKA, ANIKA THERAPEUTICS,CINGAL,HYAFF,INTEGRITY,MONOVISC,ORTHOVISC,and TACTOSET are ourtrademarks that appear in this Quarterly Report on Form 10-Q. For convenience, these trademarks appear in this Quarterly Report onForm 10-Q without ® and ™ symbols, but that practice does not mean that we will not assert, to the fullest extent under applicable law,our rights to the trademarks. This Quarterly Report on Form 10-Q also contains trademarks and trade names that are the property of Anika Therapeutics, Inc. and SubsidiariesCondensed Consolidated Statements of Operations and Comprehensive Loss Anika Therapeutics, Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders' Equity Anika Therapeutics, Inc. and SubsidiariesNotes to Condensed Consolidated Financial Statements 1.Nature of Business Anika Therapeutics, Inc. (the “Company”)is a global leader in the design, development, manufacturing, and commercializationof hyaluronic acid (HA) innovations. In partnership with clinicians, the Company’s sole focus is dedicated to delivering and advancingosteoarthritis (OA) pain management and orthopedic regenerative solutions. At the core is a passion to deliver a differentiated portfolio In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC(“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface Incorporated (“Arthrosurface”), acompany specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened theCompany's product portfolio, developed over its 30 years of expertise in HA technology, into joint preservation and restoration, In October 2024, the Company announced a strategic shift to focus on its OA Pain Management and Regenerative Solutionsbusinesses. This strategic decision resulted in the sale of Arthrosurface on October 31, 2024, and the sale of Parcus Medical on March 7, The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development bythe Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, 2.Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Companypursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accountingprinciples generally accepted in the United States (“U.S. GAAP”). The financial statements include the accounts of Anika Therapeutics,Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosuresnormally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to SEC rules and The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction withthe Company’s an